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Abstract
Background and Purpose—Rectal bleeding can occur following radiotherapy for prostate
cancer and negatively impacts quality of life for cancer survivors. Treatment and clinical factors
do not fully predict for rectal bleeding, and genetic factors may be important.
Materials and Methods—A genome-wide association study (GWAS) was performed to
identify SNPs associated with development of late rectal bleeding following radiotherapy for
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prostate cancer. Logistic regression was used to test association between 614,453 SNPs and rectal
bleeding in a discovery cohort (79 cases, 289 controls), and top-ranking SNPs were tested in a
replication cohort (108 cases, 673 controls) from four independent sites.
Results—rs7120482 and rs17630638, which tag a single locus on chromosome 11q14.3, reached
genome-wide significance for association with rectal bleeding (combined p-values 5.4×10−8 and
6.9×10−7 respectively). Several other SNPs had p-values trending towards genome-wide
significance, and a polygenic risk score including these SNPs shows a strong rank-correlation with
rectal bleeding (Sommers’ d = 5.0×10−12 in the replication cohort).
Conclusions—This GWAS identified novel genetic markers of rectal bleeding following
prostate radiotherapy. These findings could lead to development of a predictive assay to identify
patients at risk for this adverse treatment outcome so that dose or treatment modality could be
modified.
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Introduction
Prostate cancer is one of the most common cancers in the world, with approximately one
million new cases diagnosed per year worldwide [1]. Prostate cancer can be successfully
treated when detected early, by radiotherapy (brachytherapy or intensity-modulated
radiation therapy (IMRT)) and/or surgery, and risk of side effects becomes a deciding factor
when choosing among treatment options [2]. Even with improvements in precision of
radiation delivery, some men experience late adverse effects of radiotherapy for prostate
cancer, including rectal bleeding. The incidence of rectal bleeding is dependent, in part, on
dosimetry or underlying medical conditions. For example, a multivariate analysis of clinical
and patient-specific factors among approximately 780 men treated under the UK Medical
Research Council RT01 trial found that prescribed dose and age were significantly
associated with risk of rectal toxicity [3]. But, variability in dose and demographic factors
does not fully explain the variability in rectal bleeding, and prior studies suggest there are
underlying genetic risk factors [4–5].
Previous studies have investigated associations between SNPs in candidate genes, mainly
genes involved in DNA damage response and inflammation, and rectal toxicity in prostate
cancer patients treated with radiotherapy [6]. However, most of these SNPs have either been
investigated in only one study or have shown conflicting results across studies. Few, if any,
of these associations have been replicated. A large validation study was recently published
in which 92 SNPs in 46 genes were investigated in 637 prostate radiotherapy patients [7].
Five rectal endpoints (bleeding, proctitis, sphincter control, stool frequency, tenesmus) were
evaluated in patients two years after radiotherapy. None of the previously reported
associations for candidate gene SNPs could be confirmed in this project.
In order to take a broader, unbiased approach, we carried out a two-stage GWAS to identify
SNPs associated with late rectal bleeding following radiation therapy for prostate cancer.
Materials and Methods
Patient Characteristics
The study included men treated with definitive radiation for biopsy proven adenocarcinoma
of the prostate (low, intermediate and high risk). Patients were recruited from the Mount
Sinai Medical Center in the USA (MSMC), the Clinical University Hospital of Santiago de
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Compostela in Spain (CHUS), the Maastricht Radiation Oncology Clinic in the Netherlands
(MAASTRO), the Cross Cancer Institute and Tom Baker Cancer Centre in Canada (CCI),
and the Florida Radiation Oncology Group in the USA (FROG). The MSMC cohort served
as a discovery set and the pooled CHUS, MAASTRO, CCI and FROG cohorts served as a
replication set. The study was approved by the Institutional Review Boards of the respective
study sites, and all men provided informed consent.
The MSMC discovery cohort included 764 patients, of which 368 were included in the
GWAS (all cases and a randomly selected set of 289 controls). Unselected controls were
similar to selected controls with respect to clinical and demographic variables (Table 1).
Treatment included brachytherapy (206; 56%), brachytherapy with external beam radiation
therapy (EBRT) (160; 43.5%), or EBRT alone (2, 0.5%). 125I (160Gy; TG-43) was used in
patients who received brachytherapy alone and 103Pd (124Gy) in patients who also received
EBRT. The EBRT prescription dose was 45Gy in 25 fractions. All implants were performed
using a real time ultrasound guided technique previously described [8–9]. 194 patients
(52.7%) received hormonal therapy in addition to radiotherapy.
In the pooled replication set, the CHUS cohort consisted of 403 patients from the
RADIOGEN trial treated with EBRT [10]. Total delivered dose ranged from 50 to 76
(median 74) Gy with 1.8 to 2.0 Gy per fraction. 311 (77.2%) patients also received hormonal
therapy. The MAASTRO cohort consisted of 203 patients treated with EBRT alone (144
patients; 70.9%) prescribed to 68–72Gy in 2.0 Gy fractions or with brachytherapy alone (59
patients; 29.1%) prescribed to 145Gy. 111 patients (54.7%) also received hormonal therapy.
The CCI cohort consisted of 153 patients treated with EBRT. Hypo-fraction regimens were
given to 33 (21.6%) patients and consisted of 68Gy in 25 fractions or 55Gy in 16 fractions.
Standard fraction was delivered to 120 (78.4%) patients with 72 to 82Gy delivered in 1.8 to
2Gy per fraction. Hormonal therapy was given to 77 (50.3%) patients. The FROG cohort
consisted of 52 patients. The treatment regimen and technique were similar to the MSMC
group. Treatment included 125I brachytherapy (5 patients; 9.6%), 103Pd brachytherapy with
EBRT (38 patients; 73.1%), or EBRT alone (9 patients; 17.2%). 28 patients (53.8%)
received hormonal therapy as part of their treatment. EBRT patients were all treated with
IMRT technique. Total doses ranged from 64.8 to 81 Gy using 1.8Gy fractions. Total
biologically effective dose was calculated among all cohorts using previously published
methods with an /  of 2 [11].
All men were followed prospectively for development of rectal bleeding. Included patients
had at least one year of follow-up, and late (>90 days post-RT) rectal bleeding was
considered. Rectal bleeding was assessed as follows: in the MSMC and FROG patients
using the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scoring
schema; in the CHUS and CCI patients using National Cancer Institute Common Toxicity
Criteria for Adverse Events (CTCAE) version 3; and in the MAASTRO patients using a
patient self-report questionnaire, which was harmonized to the RTOG grading scheme (see
Appendix for detailed descriptions). For all cohorts, rectal bleeding grade was assigned by a
physician based on patient-reported description of symptoms. Care was taken to ensure
comparability in case/control definitions across cohorts. Patients with grade 2 or higher
rectal bleeding were considered cases and patients with grade 0 or 1 were considered
controls.
Genotyping and Quality Control
Genomic DNA was isolated from lymphocytes. DNA from men in the discovery cohort was
genotyped for ~900,000 SNPs using Affymetrix v6.0 genome-wide arrays, and genotypes
were called using Genotyping Console (Affymetrix, Santa Clara, CA). DNA from men in
the CHUS, MAASTRO and FROG replication cohorts was genotyped using Illumina iSelect
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custom SNP arrays, and genotypes were called by GenomeStudio (Illumina, San Diego,
CA). DNA from men in the CCI cohort was genotyped using Affymetrix v6.0 genome-wide
arrays, but these samples were only analyzed for SNPs included in the replication study and
present on the Illumina array. SNPs were excluded from analysis if missing in >5% of
samples (137,589 SNPs in the discovery dataset; 14 SNPs in the replication dataset), if they
had minor allele frequency (MAF) <5% (157,580 SNPs in the discovery dataset), or if they
showed deviation from Hardy-Weinberg equilibrium (p-value < 1×10−5; 5,433 SNPs in the
discovery dataset). Individuals were excluded if they showed cryptic relatedness (8 pairs) or
if they had call rate <90% (24 individuals). Duplicate samples and a trio of HapMap samples
were included in both rounds of genotyping and showed >98% concordance. PLINKv1.07
was used for quality control and SNP association tests [12].
Principal components analysis (PCA) was performed to assess and control for individual
genetic ethnicity using 11 reference populations from the International HapMap Project
[13]. PCA was performed using 860 ancestry-informative markers. SNP data processing and
PCA was carried out using R [14].
Statistical Analysis
Association between clinical and demographic variables and rectal bleeding was assessed
using chi-square test and one-way analysis of variance. IBM SPSS Statistics 19 was used for
statistical tests.
Tests for association between each SNP and rectal bleeding were carried out using
multivariable logistic regression including the first five principle components (to control for
ethnicity) as well as study site in the replication stage (to control for differences in treatment
across the four sites). Fisher’s trend method was used to combine p-values from the
discovery and replication studies [15].
A polygenic risk score was computed by assigning a numeric count of risk alleles for each
SNP and then adding together the number of risk alleles for the replicated SNPs. For SNPs
showing an additive inheritance mode, homozygotes for the risk allele were assigned 1
point, heterozygotes were assigned 0.5 points, and homozygotes for the non-risk allele were
assigned 0 points. For SNPs with either dominant or recessive inheritance mode, the
appropriate genotype categories were collapsed so that those with the risk genotype(s) were
assigned 1 point and those without the risk genotype(s) were assigned 0 points. Rank-
correlation between the polygenic risk score and rectal bleeding was assessed using Somers’
d.
Results
Among 1,572 men with prostate adenocarcinoma who met the inclusion criteria for the
study, 188 (12.0%) developed significant (≥ grade 2 or equivalent severity; Appendix 1) late
rectal bleeding. The incidence of rectal bleeding was similar across study sites: 80 out of
764 (10.5%) at MSMC; 41 out of 403 (10.2%) at CHUS; 36 out of 203 (17.7%) at
MAASTRO; 26 out of 153 (17.0%) at CCI; and 6 out of 52 (11.5%) at FROG. The mean
length of follow-up for assessing rectal bleeding was similar between cases and controls in
both the discovery and replication cohorts (50 months for cases vs. 48 months for controls in
the MSMC cohort and 40 months for cases vs. 41 months for controls in the replication).
A genome-wide association study (GWAS) was performed to identify SNPs associated with
development of rectal bleeding in the MSMC discovery cohort (79 cases and 289 controls),
and top SNPs were investigated in the pooled replication cohort (108 cases and 673
controls). Table 1 shows the characteristics of the patients included in the GWAS. On
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univariate analysis, there were no statistically significant differences (p<0.05) in age,
Gleason score, treatment modality, or use of hormonal therapy between cases and controls in
either the MSMC cohort or the pooled replication cohort. Total biologically effective dose
(BED) was similar between cases and controls in the MSMC cohort and the pooled
replication cohort, though the majority of the MSMC patients were treated with
brachytherapy whereas the replication cohort patients were largely treated with external
beam RT and received, on average, lower doses (Table 1).
After quality control, 614,453 SNPs were investigated for association with rectal bleeding in
the MSMC discovery cohort. Consistent with self-reported race/ethnicity, PCA confirmed
that the majority of the patients were of European ancestry, with approximately 25%
showing African, Hispanic, and/or Asian ancestry (Supplementary Figure 1). Inclusion of
the first five principle components in association tests adequately controlled for ethnicity as
evidenced by a low genomic inflation factor (1.02) after correction (Supplementary Figure
2). A total of 491 SNPs were identified with p-values between 3.1×10−10 and 9.9×10−4 in
the discovery cohort, and these SNPs were tested in the pooled replication cohort. A region
on chromosome 11q14.3 contained two SNPs, rs7120482 and rs17630638, which have
Fisher combined p-values reaching or near genome-wide significance (5.4×10−8 and
6.9×10−7 respectively) and show the same odds ratio directionality and inheritance model in
the discovery and replication cohorts (Supplementary Table 1). These two SNPs are in
strong linkage disequilibrium (r2=1.0 in the HapMap CEU population) and likely tag a
single risk locus. Two other SNPs were identified that have Fisher combined p-values near
genome-wide significance: rs10519410 on 4q28.3 nearest the PCDH18 gene (combined p-
value = 1.3×10−6) and rs10255878 on 7q21.3 nearest the ACN9 gene (combined p-value =
3.6×10−6). Several other SNPs showed a trend towards significance, with combined p-values
< 5.0×10−4 (Supplementary Table 1). Though each individual study site in the replication
cohort is underpowered to detect statistically significant associations, we confirmed
agreement in odds ratio directionality in each study site for all SNPs listed in Supplementary
Table 1.
In a related GWAS of erectile dysfunction following radiotherapy, a polygenic risk score
representing the sum total number of risk alleles an individual possessed, as a quantitative
measure of genetic risk, showed a stronger association signal than any single SNP alone
[16]. Here, we see a similar effect using the top 17 SNPs associated with rectal bleeding
(excluding rs17630638 and rs7111590, which are in linkage disequilibrium with a SNP
already included). After controlling for ethnicity and study site, the polygenic risk score had
an odds ratio of 3.0 (95% CI 2.4–3.9; p-value 5.4×10−18) in the discovery cohort and an
odds ratio of 1.7 (95% CI 1.5–1.9; p-value 6.4×10−13) in the replication cohort. Similarly,
there was a strong rank-correlation between number of total risk alleles out of these 17 SNPs
and rectal bleeding (Sommers’ d p-value = 1.6×10−28 in the discovery cohort; 5.0×10−12 in
the replication cohort; Table 2). When used to predict the probability of developing rectal
bleeding, the polygenic risk score produces an area under the receiver operating
characteristic curve (AUC) of 0.892 in the discovery cohort and 0.737 in the replication
cohort. It should be noted, the odds ratio and AUC for the discovery cohort is an overly
optimistic estimate precisely because this cohort was used for discovery. Furthermore, the
per-allele increase in odds of developing rectal bleeding may be non-linear over the set of
predictive SNPs, and it will be important to refine this model following validation studies.
Previous studies found SNPs in DNA damage and inflammatory response genes ( ATM,
LIG4, ERCC2CP2D6*4, MDC1, SOD2, XRCC3 and TGFB1) to be associated with rectal
toxicity. Data was available for 18 of these published SNPs in either some or all of the
patients in the current study. Two of the SNPs, rs1800935 in MSH6 and rs4803455 in
TGFB1, have dominant-model p-values <0.05, but these are not significant after correction
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for multiple comparisons (Table 3). All other SNPs available for testing had non-significant
p-values.
Discussion
The rationale for embarking upon the current study is that previous research has been
narrowly focused upon specific genes involved in radiation response and DNA repair
pathways. We sought to genotype broadly on a genome-wide level and to use the results of
the discovery GWAS to focus on a subset of SNPs for validation in replication cohorts. To
our knowledge, this is the first genome-wide approach to identify SNPs associated with late
rectal toxicity after radiotherapy. Using this approach, we identified a set of candidate SNPs
that may be useful in predicting which patients are at risk for development of rectal bleeding
following treatment.
Rectal bleeding following radiation is a microangiopathic condition with increased vascular
proliferation. The candidate genes located in proximity to some of the significant SNPs in
this study may encode products that serve roles in restraining vascular proliferation. The
SLC36A4 gene that is downstream of the two significant SNPs, rs7120482 and rs17630638,
encodes a non-proton coupled amino acid transporter that is required for normal cellular
proliferation [17]. Specifically, it modulates the activity of the mammalian target of
rapamycin complex 1 (mTORC1) signaling cascade which affects angiogenesis,
proliferation and cell survival, among other functions [17]. Interestingly, mTOR signaling
has been shown to play a role in radiosensitization in a number of studies across various
tumor types, including prostate [18–19]. SNP rs4904509 lies just upstream of FOXN3,
which was identified as a novel DNA-damage checkpoint suppressor protein in a yeast
genetic screen [20]. This SNP did not show as strong an association signal in the replication
cohort, but may warrant further investigation due to its relevant biological mechanism. Fine-
mapping studies will be needed to confirm which genes are affected by the tag SNPs
identified here before functional studies can be undertaken.
Our study provides an important replication cohort for the SNPs previously studied in the
context of rectal toxicity. None showed significant association after correction for multiple
comparisons in this dataset, which had at least 80% power to detect SNPs whose MAF is
greater than 15% and have an effect size greater than two. A few of the SNPs have very low
MAF, and some may be associated but with a small effect size and will need to be
investigated in larger cohorts.
There are a few limitations in this study. First, the discovery cohort was treated mainly with
brachytherapy whereas the replication cohort was largely treated with EBRT and had lower
mean BED (Table 1). While treatment type or dose would not confound SNP association
with rectal bleeding, these variables could act as effect modifiers, explaining in part the
difference in magnitude of the odds ratios between the discovery and replication cohorts.
Despite these treatment differences between cohorts, we were able to identify associated
SNPs, suggesting there may be genetic predictors that are non-specific for treatment
modality. Another limitation is that different scoring systems were used to assess rectal
bleeding, possibly introducing some misclassification bias. However, we believe the scoring
systems can be harmonized and that we were able to achieve consistency across cohorts.
Finally, while the rectal V100 was not significantly different between cases and controls in
the discovery cohort, this data was not available for patients in the replication cohort. It will
be important to investigate the possible interaction between rectal V100 and SNPs so that
predictive models can include both genetic and non-genetic factors.
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Using a GWAS approach, we identified a locus reaching genome-wide significance for
association with rectal bleeding. Additional validation studies are needed to both confirm
this finding and to determine whether the other SNPs with marginally significant p-values
are in fact associated with late rectal bleeding. Additional studies with larger sample sizes
may also uncover additional variants with smaller effect sizes. The current study is an
important step in the process of identifying predictors of radiotherapy toxicity that could be
used to better tailor therapy to each individual patient.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Rank-correlation between cumulative number of risk alleles summed for the top 17 SNPs and rectal bleeding
case/control status in the discovery and replication cohorts.
Number of risk alleles









0 0 0 0 1 (0.1%)
0.5 0 0 0 0
1 0 2 (0.7%) 0 4 (0.6%)
1.5 0 2 (0.7%) 0 11 (1.6%)
2 0 12 (4.2%) 0 13 (1.9%)
2.5 0 25 (8.7%) 0 33 (4.9%)
3 1 (1.3%) 25 (8.7%) 6 (5.6%) 48 (7.1%)
3.5 1 (1.3%) 44 (15.2%) 3 (2.8%) 48 (7.1%)
4 2 (2.5%) 42 (14.5%) 9 (8.4%) 95 (14.1%)
4.5 2 (2.5%) 28 (9.7%) 9 (8.4%) 86 (12.8%)
5 7 (8.9%) 33 (11.4%) 10 (9.3%) 97 (14.4%)
5.5 4 (5.1%) 32 (11.1%) 9 (8.4%) 66 (9.8%)
6 12 (15.2%) 20 (6.9%) 15 (14.0%) 49 (7.3%)
6.5 5 (6.3%) 10 (3.5%) 13 (12.1%) 40 (5.9%)
7 9 (11.4%) 3 (1.0%) 13 (12.1%) 23 (3.4%)
7.5 11 (13.9%) 7 (2.4%) 10 (9.3%) 16 (2.4%)
8 6 (7.6%) 3 (1.0%) 6 (5.6%) 7 (1.0%)
8.5 4 (5.1%) 1 (0.3%) 1 (0.9%) 6 (0.9%)
9 5 (6.3%) 0 3 (2.8%) 3 (0.4%)
9.5 5 (6.3%) 0 0 3 (0.4%)
10 2 (2.5%) 0 0 1 (0.1%)
10.5 2 (2.5%) 0 0 0
11 1 (1.3%) 0 0 0
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